|
Clemastine Fumarate Clinical Trials
3 actively recruiting trials across 2 locations
Also known as: Clemastine, Dayhist, Dayhist Allergy, Tavegyl, clemastine
Pipeline
Phase 3: 1Phase 1/2: 2
Top Sponsors
- University of California, San Francisco1
- National Institute of Allergy and Infectious Diseases (NIAID)1
- Amsterdam UMC, location VUmc1
Indications
- Multiple Sclerosis3
- Multiple Sclerosis Benign1
- Multiple Sclerosis Brain Lesion1
- Internuclear Ophthalmoplegia1
- Multiple Sclerosis Relapse1
Other1 trial
San Francisco, California1 trial
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Sandler Neurosciences Building, Neurological Clinical Research Unit
Phase 1/2
Bethesda, Maryland1 trial
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
National Institutes of Health Clinical Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.